GB2553685A - Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis - Google Patents

Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis Download PDF

Info

Publication number
GB2553685A
GB2553685A GB1714549.1A GB201714549A GB2553685A GB 2553685 A GB2553685 A GB 2553685A GB 201714549 A GB201714549 A GB 201714549A GB 2553685 A GB2553685 A GB 2553685A
Authority
GB
United Kingdom
Prior art keywords
matrix metalloproteinases
angiogenesis
inhibitors
novel
éthynylxanthines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1714549.1A
Other versions
GB2553685A8 (en
GB2553685B (en
Inventor
Arsenjans Pavels
Kauss Valerjans
Vasiljeva Jelena
Kalvins Ivars
Domracheva Llona
Shestakova Irina
Gulbe Anita
Kanepe Lapsa Iveta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Latvian Institute of Organic Synthesis
Original Assignee
Latvian Institute of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Institute of Organic Synthesis filed Critical Latvian Institute of Organic Synthesis
Publication of GB2553685A publication Critical patent/GB2553685A/en
Publication of GB2553685A8 publication Critical patent/GB2553685A8/en
Application granted granted Critical
Publication of GB2553685B publication Critical patent/GB2553685B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel ethynylxanthine derivatives of formula (I) which exhibit ability selectively suppress matrix metalloproteinases and therefore may act as inhibitors of angiogenesis, methods for their synthesis and use for the treatment and/or prevention of various diseases and disorders caused by overexpression of matrix metalloproteinases by administration of such substances.
GB1714549.1A 2015-03-27 2015-03-27 Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis Active GB2553685B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/LV2015/000002 WO2016159746A1 (en) 2015-03-27 2015-03-27 Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis

Publications (3)

Publication Number Publication Date
GB2553685A true GB2553685A (en) 2018-03-14
GB2553685A8 GB2553685A8 (en) 2018-04-18
GB2553685B GB2553685B (en) 2020-06-10

Family

ID=52815228

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1714549.1A Active GB2553685B (en) 2015-03-27 2015-03-27 Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis

Country Status (2)

Country Link
GB (1) GB2553685B (en)
WO (1) WO2016159746A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007469A1 (en) * 2002-07-12 2004-01-22 Warner-Lambert Company Llc New alkynylated quinazolin compounds as mmp-13 inhibitors
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2008077557A1 (en) * 2006-12-22 2008-07-03 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective a2a receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2166948C1 (en) 2000-05-29 2001-05-20 Центральный научно-исследовательский рентгенорадиологический институт Method for treating gliomae aggravated with epileptic syndrome
US8435541B2 (en) 2010-09-02 2013-05-07 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
AU2014228206C1 (en) 2013-03-15 2018-10-25 Hydra Biosciences, Llc Substituted xanthines and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007469A1 (en) * 2002-07-12 2004-01-22 Warner-Lambert Company Llc New alkynylated quinazolin compounds as mmp-13 inhibitors
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2008077557A1 (en) * 2006-12-22 2008-07-03 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective a2a receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACTS SERVICE COLUMBUS OHIO 12/06/2006 *

Also Published As

Publication number Publication date
WO2016159746A1 (en) 2016-10-06
GB2553685A8 (en) 2018-04-18
GB2553685B (en) 2020-06-10

Similar Documents

Publication Publication Date Title
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2020006438A (en) Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA033343B1 (en) Compounds inhibiting rip2 kinase, pharmaceutical composition based thereon and use thereof for the treatment of diseases mediated by rip2 kinase
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2020011449A (en) Oxysterols and methods of use thereof.
MY197698A (en) Oxysterols and methods of use thereof
EA033163B1 (en) Inhibitors of glutaminase
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
MX2017014035A (en) Solid forms.
SA520412335B1 (en) Oxy-fluoropiperidine derivatives as kinase inhibitor
UA118610C2 (en) Spirocyclic inhibitors of cathepsin c
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2019006863A (en) Heparanase inhibitors and use thereof.
MX2017009849A (en) Monomethylfumarate prodrug compositions.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2018007517A (en) Tricyclic compounds and compositions as kinase inhibitors.
MX2014003455A (en) Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands.
MX2019014436A (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors.
GB2553685A (en) Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis